» Articles » PMID: 29738382

The Comparison of Midazolam and Propofol in Gastrointestinal Endoscopy: A Systematic Review and Meta-analysis

Overview
Date 2018 May 9
PMID 29738382
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Midazolam and propofol are both used for sedation in gastrointestinal endoscopy. We conducted a systematic review and meta-analysis to compare the efficacy and safety of midazolam and propofol in gastrointestinal endoscopy.

Materials And Methods: PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials assessing the effect of midazolam versus propofol on sedation in gastrointestinal endoscopy are included. Two investigators have independently searched for articles, extracted data, and assessed the quality of included studies. This meta-analysis was performed using the random-effect model.

Results: Five randomized controlled trials involving 552 patients were included in the meta-analysis. Overall, compared with midazolam sedation during gastrointestinal endoscopy, propofol sedation results in higher endoscopist satisfaction scores during gastrointestinal endoscopy than midazolam [standard mean difference (Std. MD)=-0.71; 95% confidence interval (CI)=-1.05 to -0.37; P<0.0001), but the comparison shows no remarkable influence on patient satisfaction scores between midazolam and propofol (Std. MD=-0.34; 95% CI=-0.88 to 0.20; P=0.21), procedure time (Std. MD=0.14; 95% CI=-0.13 to 0.42; P=0.31), hypoxia [risk ratio (RR)=0.86; 95% CI=0.53-1.38; P=0.53), and bradycardia (RR=1.05; 95% CI=0.54-2.06; P=0.89). In addition, propofol shows higher incidence of hypotension than midazolam (RR=0.58; 95% CI=0.34-0.99; P=0.04).

Conclusions: When compared with midazolam sedation for gastrointestinal endoscopy, propofol sedation results in higher endoscopist satisfaction scores, but may increase the incidence of hypotension.

Citing Articles

Effect of intravenous lidocaine on outcomes in patients receiving propofol for gastrointestinal endoscopic procedures: an updated systematic review and meta-analysis.

Wu F, Zhan L, Xu W, Bian J Eur J Clin Pharmacol. 2023; 80(1):39-52.

PMID: 37962581 DOI: 10.1007/s00228-023-03589-y.


Effectiveness and safety of an atropine/midazolam and target controlled infusion propofol-based moderate sedation protocol during percutaneous endoscopic transgastric jejunostomy procedures in Parkinson's disease: a real-life retrospective....

Gravina A, Pellegrino R, De Micco R, Dellavalle M, Grasso A, Palladino G Front Med (Lausanne). 2023; 10:1233575.

PMID: 37771983 PMC: 10523572. DOI: 10.3389/fmed.2023.1233575.


The safety and efficacy of remimazolam tosylate combined with propofol in upper gastrointestinal endoscopy: A multicenter, randomized clinical trial.

Wei A, Ma S, Dou Y, Wang X, Wu J, Zhou S PLoS One. 2023; 18(8):e0282930.

PMID: 37535618 PMC: 10399878. DOI: 10.1371/journal.pone.0282930.


Comparative Study of Moderate Sedation with Propofol Versus Propofol Combined with Midazolam for Ambulatory Care Digestive Endoscopic Procedures.

Popa-Ion D, Gheonea D, Denicu M, Chiutu L Curr Health Sci J. 2023; 48(3):292-302.

PMID: 36815084 PMC: 9940920. DOI: 10.12865/CHSJ.48.03.07.


Feasibility of Continuous Monitoring of Endoscopy Performance and Adverse Events: A Single-Center Experience.

Zandanell S, Gensluckner S, Wolkersdoerfer G, Berr F, Dienhart C, Gantschnigg A Cancers (Basel). 2023; 15(3).

PMID: 36765682 PMC: 9913416. DOI: 10.3390/cancers15030725.